Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses

H. Kamijuku; Y. Nagata; X. Jiang; T. Ichinohe; T. Tashiro; K. Mori; M. Taniguchi; K. Hase; H. Ohno; T. Shimaoka; S. Yonehara; T. Odagiri; M. Tashiro; T. Sata; H. Hasegawa; K. I. Seino

doi:10.1038/mi.2008.2

Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses

H. Kamijuku, Y. Nagata, X. Jiang, T. Ichinohe, T. Tashiro, K. Mori, M. Taniguchi, K. Hase, H. Ohno, T. Shimaoka, S. Yonehara, T. Odagiri, M. Tashiro, T. Sata, H. Hasegawa, K. I. Seino

Research output: Contribution to journal › Article › peer-review

87 Citations (Scopus)

Abstract

In a nasal vaccine against influenza, the activation of natural killer T (NKT) cells by intranasal coadministration of α-galactosylceramide (α-GalCer) can potently enhance protective immune responses. The results of this study show that the NKT cell-activated nasal vaccine can induce an effective cross-protection against different strains of influenza virus, including H5 type. To analyze the mechanism of NKT cell activation by this nasal vaccine, we prepared fluorescence-labeled α-GalCer by which we detect a direct interaction between NKT cells and α-GalCer-stored dendritic cells in nasal mucosa-associated tissues. Accordingly, although very few NKT cells exist at mucosa, the nasal vaccination induced a localized increase in NKT cell population, which is partly dependent on CXCL16/CXCR6. Furthermore, we found that NKT cell activation stimulates mucosal IgA production by a mechanism that is dependent on interleukin (IL)-4 production. These results strengthen the basis of nasal vaccination via NKT cell activation, which can induce immune cross-protection.

Original language	English
Pages (from-to)	208-218
Number of pages	11
Journal	Mucosal Immunology
Volume	1
Issue number	3
DOIs	https://doi.org/10.1038/mi.2008.2
Publication status	Published - 2008 May
Externally published	Yes

ASJC Scopus subject areas

Immunology and Allergy
Immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/mi.2008.2

Cite this

Kamijuku, H., Nagata, Y., Jiang, X., Ichinohe, T., Tashiro, T., Mori, K., Taniguchi, M., Hase, K., Ohno, H., Shimaoka, T., Yonehara, S., Odagiri, T., Tashiro, M., Sata, T., Hasegawa, H., & Seino, K. I. (2008). Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses. Mucosal Immunology, 1(3), 208-218. https://doi.org/10.1038/mi.2008.2

Kamijuku, H, Nagata, Y, Jiang, X, Ichinohe, T, Tashiro, T, Mori, K, Taniguchi, M, Hase, K, Ohno, H, Shimaoka, T, Yonehara, S, Odagiri, T, Tashiro, M, Sata, T, Hasegawa, H & Seino, KI 2008, 'Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses', Mucosal Immunology, vol. 1, no. 3, pp. 208-218. https://doi.org/10.1038/mi.2008.2

@article{c39d4bbba397440aafaccd5e63187823,

title = "Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses",

abstract = "In a nasal vaccine against influenza, the activation of natural killer T (NKT) cells by intranasal coadministration of α-galactosylceramide (α-GalCer) can potently enhance protective immune responses. The results of this study show that the NKT cell-activated nasal vaccine can induce an effective cross-protection against different strains of influenza virus, including H5 type. To analyze the mechanism of NKT cell activation by this nasal vaccine, we prepared fluorescence-labeled α-GalCer by which we detect a direct interaction between NKT cells and α-GalCer-stored dendritic cells in nasal mucosa-associated tissues. Accordingly, although very few NKT cells exist at mucosa, the nasal vaccination induced a localized increase in NKT cell population, which is partly dependent on CXCL16/CXCR6. Furthermore, we found that NKT cell activation stimulates mucosal IgA production by a mechanism that is dependent on interleukin (IL)-4 production. These results strengthen the basis of nasal vaccination via NKT cell activation, which can induce immune cross-protection.",

author = "H. Kamijuku and Y. Nagata and X. Jiang and T. Ichinohe and T. Tashiro and K. Mori and M. Taniguchi and K. Hase and H. Ohno and T. Shimaoka and S. Yonehara and T. Odagiri and M. Tashiro and T. Sata and H. Hasegawa and Seino, {K. I.}",

note = "Funding Information: We are grateful to Wilina Lim (Department of Health, The Government of Hong Kong) for providing us the A / Vietnam / 1194 / 04 (H5N1) influenza virus strain, U. Suzuki and Dr Komase (Kitasato Institute, Saitama, Japan) for providing us the vaccines, and E. Berglund for reading and editing the manuscript. This work was partly supported by RIKEN Strategic Research Programs for R & D (the President {\textquoteright}s Discretionary Fund), The Uehara Memorial Foundation, The Innovation Center in Kanagawa Academy of Science and Technology, Ministry of Health, Labor, and Welfare, and Research on Health Sciences focusing on Drug Innovation. T. Ichinohe is a research fellow of the Japan Society for the Promotion of Science.",

year = "2008",

month = may,

doi = "10.1038/mi.2008.2",

language = "English",

volume = "1",

pages = "208--218",

journal = "Mucosal Immunology",

issn = "1933-0219",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses

AU - Kamijuku, H.

AU - Nagata, Y.

AU - Jiang, X.

AU - Ichinohe, T.

AU - Tashiro, T.

AU - Mori, K.

AU - Taniguchi, M.

AU - Hase, K.

AU - Ohno, H.

AU - Shimaoka, T.

AU - Yonehara, S.

AU - Odagiri, T.

AU - Tashiro, M.

AU - Sata, T.

AU - Hasegawa, H.

AU - Seino, K. I.

N1 - Funding Information: We are grateful to Wilina Lim (Department of Health, The Government of Hong Kong) for providing us the A / Vietnam / 1194 / 04 (H5N1) influenza virus strain, U. Suzuki and Dr Komase (Kitasato Institute, Saitama, Japan) for providing us the vaccines, and E. Berglund for reading and editing the manuscript. This work was partly supported by RIKEN Strategic Research Programs for R & D (the President ’s Discretionary Fund), The Uehara Memorial Foundation, The Innovation Center in Kanagawa Academy of Science and Technology, Ministry of Health, Labor, and Welfare, and Research on Health Sciences focusing on Drug Innovation. T. Ichinohe is a research fellow of the Japan Society for the Promotion of Science.

PY - 2008/5

Y1 - 2008/5

N2 - In a nasal vaccine against influenza, the activation of natural killer T (NKT) cells by intranasal coadministration of α-galactosylceramide (α-GalCer) can potently enhance protective immune responses. The results of this study show that the NKT cell-activated nasal vaccine can induce an effective cross-protection against different strains of influenza virus, including H5 type. To analyze the mechanism of NKT cell activation by this nasal vaccine, we prepared fluorescence-labeled α-GalCer by which we detect a direct interaction between NKT cells and α-GalCer-stored dendritic cells in nasal mucosa-associated tissues. Accordingly, although very few NKT cells exist at mucosa, the nasal vaccination induced a localized increase in NKT cell population, which is partly dependent on CXCL16/CXCR6. Furthermore, we found that NKT cell activation stimulates mucosal IgA production by a mechanism that is dependent on interleukin (IL)-4 production. These results strengthen the basis of nasal vaccination via NKT cell activation, which can induce immune cross-protection.

AB - In a nasal vaccine against influenza, the activation of natural killer T (NKT) cells by intranasal coadministration of α-galactosylceramide (α-GalCer) can potently enhance protective immune responses. The results of this study show that the NKT cell-activated nasal vaccine can induce an effective cross-protection against different strains of influenza virus, including H5 type. To analyze the mechanism of NKT cell activation by this nasal vaccine, we prepared fluorescence-labeled α-GalCer by which we detect a direct interaction between NKT cells and α-GalCer-stored dendritic cells in nasal mucosa-associated tissues. Accordingly, although very few NKT cells exist at mucosa, the nasal vaccination induced a localized increase in NKT cell population, which is partly dependent on CXCL16/CXCR6. Furthermore, we found that NKT cell activation stimulates mucosal IgA production by a mechanism that is dependent on interleukin (IL)-4 production. These results strengthen the basis of nasal vaccination via NKT cell activation, which can induce immune cross-protection.

UR - http://www.scopus.com/inward/record.url?scp=42149161737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42149161737&partnerID=8YFLogxK

U2 - 10.1038/mi.2008.2

DO - 10.1038/mi.2008.2

M3 - Article

C2 - 19079180

AN - SCOPUS:42149161737

VL - 1

SP - 208

EP - 218

JO - Mucosal Immunology

JF - Mucosal Immunology

SN - 1933-0219

IS - 3

ER -

Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this